Advice
In the absence of a submission from the holder of the marketing authorisation
erlotinib (Tarceva) in combination with gemcitabine is not recommended for use within NHSScotland for the treatment of patients with metastatic pancreatic cancer.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- Erlotinib (Tarceva)
- SMC ID:
- 382/07
- Indication:
- metastatic pancreatic cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 July 2007